Matches in SemOpenAlex for { <https://semopenalex.org/work/W2801339987> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2801339987 endingPage "130.22" @default.
- W2801339987 startingPage "130.22" @default.
- W2801339987 abstract "Abstract Vα24-invariant Natural Killer T cells (NKTs) have potent antitumor properties and are being developed for cellular immunotherapy of cancer. Such therapy requires extensive ex vivo expansion of NKTs while preserving their longevity and function. In a recent report from our group, CD62L+ subset of NKTs has been shown to have longer persistence in vivo and stronger antitumor activity than CD62L− counterpart. However, the requirements for the preservation of CD62L+ NKTs during ex vivo expansion remain largely unknown. The gene expression analysis comparing CD62L+ and CD62L− NKTs revealed a significantly higher expression level of IL-21R mRNA in the former. FACS analysis confirmed the finding at the cell surface protein level. These led us to hypothesize that IL-21 preferentially supports CD62L+ NKTs. To test this hypothesis, we expanded primary human peripheral blood NKTs using in vitro stimulation with their cognate antigen, α-galactosylceramide. The culture was supplemented with IL-2, IL-21, or both cytokines. We found that in contrast to IL-2, IL-21 alone failed to support NKT-cell expansion. A combination of IL-2 and IL-21 led to similar absolute numbers of NKTs compared with IL-2 alone. However, the proportion of CD62L+ NKT-cell subset was significantly higher in the culture with IL-2/IL-21 combination compared with IL-2 alone after both primary and secondary expansions. Furthermore, after transfer to NSG mice, IL2/IL-21-expanded NKTs persisted significantly longer and had higher therapeutic efficacy in a lymphoma model compared with IL-2-expanded NKTs. Our results suggest that inclusion of IL-21 in the NKT-cell expansion protocol, which currently uses IL-2 alone, would increase antitumor potential of NKT cell therapy." @default.
- W2801339987 created "2018-05-17" @default.
- W2801339987 creator A5001965273 @default.
- W2801339987 creator A5016553017 @default.
- W2801339987 creator A5021496243 @default.
- W2801339987 creator A5042047012 @default.
- W2801339987 creator A5063825630 @default.
- W2801339987 creator A5073342430 @default.
- W2801339987 creator A5088896388 @default.
- W2801339987 date "2017-05-01" @default.
- W2801339987 modified "2023-09-25" @default.
- W2801339987 title "IL-21 maintains CD62L expression during NKT-cell <i>ex vivo</i> expansion and enhances antitumor activity of NKT cell therapy <i>in vivo</i>" @default.
- W2801339987 doi "https://doi.org/10.4049/jimmunol.198.supp.130.22" @default.
- W2801339987 hasPublicationYear "2017" @default.
- W2801339987 type Work @default.
- W2801339987 sameAs 2801339987 @default.
- W2801339987 citedByCount "0" @default.
- W2801339987 crossrefType "journal-article" @default.
- W2801339987 hasAuthorship W2801339987A5001965273 @default.
- W2801339987 hasAuthorship W2801339987A5016553017 @default.
- W2801339987 hasAuthorship W2801339987A5021496243 @default.
- W2801339987 hasAuthorship W2801339987A5042047012 @default.
- W2801339987 hasAuthorship W2801339987A5063825630 @default.
- W2801339987 hasAuthorship W2801339987A5073342430 @default.
- W2801339987 hasAuthorship W2801339987A5088896388 @default.
- W2801339987 hasConcept C139563560 @default.
- W2801339987 hasConcept C150903083 @default.
- W2801339987 hasConcept C203014093 @default.
- W2801339987 hasConcept C207001950 @default.
- W2801339987 hasConcept C26291073 @default.
- W2801339987 hasConcept C2776090121 @default.
- W2801339987 hasConcept C2777701055 @default.
- W2801339987 hasConcept C2778607024 @default.
- W2801339987 hasConcept C502942594 @default.
- W2801339987 hasConcept C86803240 @default.
- W2801339987 hasConcept C8891405 @default.
- W2801339987 hasConceptScore W2801339987C139563560 @default.
- W2801339987 hasConceptScore W2801339987C150903083 @default.
- W2801339987 hasConceptScore W2801339987C203014093 @default.
- W2801339987 hasConceptScore W2801339987C207001950 @default.
- W2801339987 hasConceptScore W2801339987C26291073 @default.
- W2801339987 hasConceptScore W2801339987C2776090121 @default.
- W2801339987 hasConceptScore W2801339987C2777701055 @default.
- W2801339987 hasConceptScore W2801339987C2778607024 @default.
- W2801339987 hasConceptScore W2801339987C502942594 @default.
- W2801339987 hasConceptScore W2801339987C86803240 @default.
- W2801339987 hasConceptScore W2801339987C8891405 @default.
- W2801339987 hasIssue "1_Supplement" @default.
- W2801339987 hasLocation W28013399871 @default.
- W2801339987 hasOpenAccess W2801339987 @default.
- W2801339987 hasPrimaryLocation W28013399871 @default.
- W2801339987 hasRelatedWork W17784216 @default.
- W2801339987 hasRelatedWork W2042235665 @default.
- W2801339987 hasRelatedWork W2052793100 @default.
- W2801339987 hasRelatedWork W2095267346 @default.
- W2801339987 hasRelatedWork W2095967285 @default.
- W2801339987 hasRelatedWork W2142194554 @default.
- W2801339987 hasRelatedWork W2150316436 @default.
- W2801339987 hasRelatedWork W2165882786 @default.
- W2801339987 hasRelatedWork W2415014615 @default.
- W2801339987 hasRelatedWork W29274827 @default.
- W2801339987 hasVolume "198" @default.
- W2801339987 isParatext "false" @default.
- W2801339987 isRetracted "false" @default.
- W2801339987 magId "2801339987" @default.
- W2801339987 workType "article" @default.